Eloralintide Interactions: Alcohol, Caffeine, Food and Other Compounds

What the Published Literature Actually Covers

Eloralintide, also identified in the literature by the development code LY3841136, was described in a 2025 report that traced the molecule from discovery and preclinical pharmacology through a clinical proof-of-concept stage as a novel amylin receptor agonist for the treatment of obesity (PMID 41109426). Two subsequent reviews placed the compound inside a broader class: a 2026 pharmacology review of amylin-based pharmacotherapy framed the class as part of a search for better-tolerated weight-loss drugs beyond GLP-1 (PMID 42586227), and a 2026 review of experimental data and early-phase clinical trials positioned amylin analogs as an emerging class of weight-loss therapy (PMID 42452898).

None of those three publications describes a dedicated interaction study pairing eloralintide with alcohol, caffeine, a defined meal challenge, a fasting protocol, or another drug or supplement. That absence is the single most important fact on this page. Where this page discusses a combination, it separates two very different things: what studies report, and mechanistic reasoning that researchers use when no interaction data exist. This page is for educational purposes only and is not medical advice; consult a licensed physician about any compound, combination or medical decision.

Interaction Evidence at a Glance

Eloralintide and Alcohol

What studies report: no alcohol co-administration study with eloralintide appears in the verified literature. The discovery-to-proof-of-concept report characterised the molecule's pharmacology and early clinical development rather than beverage or drug interactions (PMID 41109426), and neither 2026 class review described an alcohol challenge in amylin analog trials (PMID 42586227).

Mechanistic reasoning, not trial evidence: researchers discussing amylin receptor agonists generally start from amylin's role as a pancreatic hormone that slows gastric emptying and signals satiation, a mechanism summarised across reviews of the class (PMID 42452898). Because the rate at which the stomach empties into the small intestine is one determinant of how quickly ethanol reaches the systemic circulation, pharmacologists treat any gastric-emptying-modifying agent as a theoretical variable for alcohol absorption kinetics. A second line of reasoning concerns overlapping symptoms: nausea is the tolerability signal that dominates discussion of appetite-suppressing peptides in the reviews of this class (PMID 42586227), and alcohol independently provokes gastrointestinal symptoms, so investigators note that overlapping symptom profiles can complicate attribution in trial settings. Neither line of reasoning has been tested for eloralintide, and neither should be read as a prediction of magnitude, direction or clinical consequence.

Eloralintide and Caffeine

What studies report: nothing. No caffeine pharmacokinetic study, no coffee or energy-drink co-administration arm, and no stimulant combination cohort is described in the eloralintide literature reviewed here (PMID 41109426). The early-phase trial review of amylin analogs likewise did not describe caffeine interaction arms among the trials it surveyed (PMID 42452898).

Mechanistic reasoning, not trial evidence: two mechanisms are usually raised in discussions of peptides of this type. The first is absorption: caffeine is absorbed largely in the upper gastrointestinal tract, so the gastric-emptying effects attributed to amylin receptor agonism in class reviews are the usual starting point for a theoretical pharmacokinetic question (PMID 42452898). The second is metabolic route: peptide therapeutics are typically cleared by proteolytic degradation rather than hepatic cytochrome P450 enzymes, which is the reason researchers consider classical CYP1A2-mediated interactions — the pathway relevant to caffeine — an unlikely locus of interaction for a peptide. That is a class-level inference about peptide pharmacology, not a finding reported for eloralintide in any of the cited papers.

Food, Meal Timing and Fasting

What studies report: amylin itself is characterised in the class literature as a hormone co-secreted with insulin that contributes to meal-related satiation and to the control of food intake and body weight, which is the biological rationale reviews give for developing amylin analogs as weight-loss therapy (PMID 42452898). The eloralintide report described the molecule's progression from discovery through preclinical pharmacology to clinical proof of concept in obesity, rather than a formal food-effect or meal-timing study (PMID 41109426).

Mechanistic reasoning, not trial evidence: because the pharmacology of this class is described as acting on satiation signalling and gastric emptying (PMID 42586227), researchers commonly discuss food-related variables in two directions. One is whether meal composition or size changes the subjective intensity of gastrointestinal effects; the other is whether reduced spontaneous intake alters total energy and protein consumption over time. Formal fasting protocols — time-restricted eating windows, alternate-day approaches — have not been studied alongside eloralintide in any of the cited publications, so statements pairing them are speculation about mechanism rather than reported outcomes.

Combinations With Other Drugs and Peptides

Incretin-based agents

The most frequently discussed pairing at class level is amylin pharmacology alongside incretin-based therapy: the 2026 pharmacology review is framed explicitly around what lies beyond GLP-1 and the search for better-tolerated weight-loss drugs, situating amylin-based agents relative to that established class (PMID 42586227). The early-phase trial review similarly surveyed experimental data and early clinical development for amylin analogs as a therapeutic class (PMID 42452898). Those are class-level discussions of drug development strategy. They are not an eloralintide-specific combination trial, and the cited papers do not report combination outcomes for eloralintide with a named incretin agent.

Orally administered medications

Mechanistic reasoning, not trial evidence: agents that slow gastric emptying are conventionally examined for their effect on the absorption profile of oral drugs, because the timing of gastric delivery influences how quickly an oral compound reaches its absorption site. Since gastric emptying is part of the described pharmacology of amylin receptor agonism in the class reviews (PMID 42452898), this is the question regulators and pharmacologists typically ask of a new agent in the class. No such data for eloralintide appear in the cited literature.

Supplements, nicotine and recreational compounds

No study in the verified set examined eloralintide with creatine, protein supplements, vitamins, nicotine or any recreational substance. Where no data exist, the honest description is simply that: an untested combination, with no published pharmacokinetic, pharmacodynamic or tolerability observation to describe (PMID 41109426).

Gastrointestinal Tolerability: What Studies Report

Tolerability is the axis on which the class literature is organised. The 2026 pharmacology review framed amylin-based pharmacotherapy around the search for better-tolerated weight-loss drugs, an aim that reflects how prominently gastrointestinal adverse events such as nausea and vomiting feature in the weight-loss pharmacotherapy field (PMID 42586227). The review of experimental data and early-phase clinical trials likewise assessed amylin analogs across efficacy and tolerability as the class advanced through early clinical development (PMID 42452898). For eloralintide specifically, the discovery-to-proof-of-concept publication is the primary source describing its preclinical and early clinical characterisation (PMID 41109426).

Because no combination arms were described, none of these publications reports whether alcohol, caffeine, meal composition or concomitant medication changed the frequency or intensity of adverse events with eloralintide. Statements that a combination worsens or improves tolerability would not be supported by the cited record.

How Researchers Reason When No Interaction Study Exists

1. Identify the clearance route. Peptides are generally degraded proteolytically, which is why investigators consider hepatic enzyme-mediated interactions less likely for peptide agents than for small molecules — a general pharmacology principle rather than an eloralintide finding.
2. Look for shared physiology. Gastric emptying is the mechanism most often cited for amylin receptor agonists in class reviews, making absorption-timing questions the leading theoretical concern (PMID 42452898).
3. Look for overlapping adverse-event profiles. Where two agents can produce the same symptom, attribution becomes difficult, which is one reason tolerability is emphasised in reviews of this class (PMID 42586227).
4. Label the inference. Mechanistic plausibility is not measurement; the cited eloralintide publication reports development-stage pharmacology, not interaction outcomes (PMID 41109426).

Evidence Gaps

• No published alcohol, caffeine or food-effect study with eloralintide was identified in the cited literature (PMID 41109426).
• No published drug–drug interaction study for eloralintide with oral medications, incretin-based agents or other peptides appears in the cited reviews (PMID 42586227).
• Class-level conclusions about amylin analogs derive largely from experimental data and early-phase clinical trials, a stage at which long-term and combination questions typically remain open (PMID 42452898).

Readers interested in the underlying pharmacology and trial record for this molecule can review the compound overview on the eloralintide learn page, which covers mechanism, development stage and what researchers reported in the primary publication.

References

• Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept (Molecular Metabolism, 2025)
• Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs (Pharmacological Research, 2026)
• Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials (Diabetes, Obesity & Metabolism, 2026)